Development and validation of bile acid profile-based scoring system for identification of biliary atresia: a prospective study
bit.ly shows its articles on its own site.
Read the article on bit.ly ↗Article · Jul 2020 · 1 min read
In brief
In brief
Researchers developed and validated a bile acid-based scoring system to distinguish biliary atresia from other causes of infantile cholestasis. The system combines glycochenodeoxycholic acid/chenodeoxycholic acid ratio, clay stool presence, and gamma-glutamyl transferase levels, achieving 90% sensitivity and 80% specificity in validation testing.
Written by the GCMD Library team from the article.
Background: Early distinguishing biliary atresia from other causes of infantile cholestasis remains a major challenge. We aimed to develop and validate a scoring system based on bile acid for identification of biliary atresia.
Methods: In a prospective study, a total of 141 infants with cholestasis were enrolled in two sets (derivation cohort, n = 66; validation cohort, n = 75) from 2014 to 2018. Variables with significant difference between biliary atresia and non-biliary atresia infants were selected in the derivation cohort. Then, a scoring system including those variables was designed and validated.
Results: Among 66 patients in the derivation cohort, 34 (51.5%) had biliary atresia. A scoring system was proposed with the following variables: glycochenodeoxycholic acid/chenodeoxycholic acid, clay stool, and gamma-glutamyl transferase. The total score ranged from 0 to 41, and a cutoff value of 15 identified biliary atresia with an area under receiver operating characteristic curve of 0.87 (95% confidence interval, 0.77-0.94), sensitivity of 85.3%, and specificity of 81.3% in the derivation cohort; these values were also confirmed in a validation cohort with a sensitivity of 90.0% and specificity of 80.0%.
Conclusions: The proposed simple scoring system had good diagnostic accuracy for estimating the risk of biliary atresia in infants with cholestasis.
DOI: 10.1186/s12887-020-02169-8